OTC: JWCTF - JW (Cayman) Therapeutics Co. Ltd

Rentabilité sur six mois: -36.47%
Rendement en dividendes: 0.00%
Secteur: Healthcare

Calendrier des promotions JW (Cayman) Therapeutics Co. Ltd

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise JW (Cayman) Therapeutics Co. Ltd

JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacturing, and marketing of anti-tumor drugs in the People's Republic of China. It offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of a range of hematological cancers.

plus de détails
The company's pipeline products include JWCAR129, an autologous CAR-T therapy for the treatment of multiple myeloma; JWATM204, a TCR T-cell therapy candidate for the treatment of HCC; and JWATM203, an autologous T-cell receptor mimic T-cell therapy targeting alpha-fetoprotein for the treatment of hepatocellular carcinoma. JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, China.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета cny
Сайт https://www.jwtherapeutics.com
Цена ао 0.162
Changement de prix par jour: -0% (0.162)
Changement de prix par semaine: -0% (0.162)
Changement de prix par mois: -0% (0.162)
Changement de prix sur 3 mois: -0% (0.162)
Changement de prix sur six mois: -36.47% (0.255)
Changement de prix par an: -37.69% (0.26)
Evolution du prix sur 3 ans: -85.07% (1.085)
Evolution des prix depuis le début de l'année: -36.47% (0.255)
Tous les paramètres

Sous-estimation

Nom Signification Grade
P/S 4.52 3
P/BV 0.4665 10
P/E 0 0
EV/EBITDA -0.2077 0
Total: 5.38

Efficacité

Nom Signification Grade
ROA, % -35.79 0
ROE, % -45.61 0
Total: 0

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Devoir

Nom Signification Grade
Debt/EBITDA -0.588 10
Total: 9.6

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % 3070.82 10
Rentabilité Ebitda, % 108.61 10
Rentabilité EPS, % 9.47 2
Total: 6.2
Plus de détails

Établissements Volume Partager, %
DFA Emerging Markets Small Cap Series 467500 0.11
Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund 336309 0.08
DFA Emerging Markets Core Equity Portfolio 98500 0.02
Dimensional ETF Tr-Dimensional Emerging Markets Core Equity 2 ETF 95500 0.02
SPDR (R) Idx Shares-SPDR (R) S&P (R) China ETF 76500 0.02
Dimensional ETF Tr-Dimensional World ex U.S. Core Equity 2 ETF 69500 0.02
DFA Investment Dimensions-World Ex U.S. Core Equity Port 55500 0.01
SPDR (R) Idx Shares-SPDR (R) Emerging Markets Small Cap ETF 42350 0.01
DFA Investment Dimensions-DFA Emerging Markets Targeted Value Port 38000 0.01
Avantis Emerging Markets Equity ETF 36000 0.01



Superviseur Titre d'emploi Paiement Année de naissance
Dr. Yiping Li M.D. Co-Founder & Interim Chairman 836.74k 1964 (61 année)
Cao Xiaoping Ph.D. Senior Vice President of Tech Operations N/A
Dr. Shaun Paul Cordoba Ph.D. Senior VP & Chief Scientific Officer N/A 1980 (45 années)
Mr. Raymond J. Hage Jr. Senior Vice President of Corporate Development N/A 1968 (57 années)
Mr. Mark J. Gilbert M.D. Senior Advisor & Acting Chief Medical Officer N/A
Ms. Ka Man Ng A.C.I.S., A.C.S. Company Secretary N/A 1978 (47 années)
Mr. Qiang Ma Senior VP & Chief Commercial Officer N/A 1978 (47 années)
Ms. Yun Qin Senior Vice President of Clinical Sciences & Medical Services N/A 1982 (43 année)
Dr. Su Yang Senior Vice President Of Clinical Research & PMO N/A 1979 (46 années)
Mr. Min Liu CEO & Executive Director 1973 (52 année)

Adresse: China, Shanghai, Building B - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://www.jwtherapeutics.com